Showing results (1831-1840 of 2,544) with videos related to

Sort By:
Pageof 255
Journal of Cancer Research and Clinical Oncology|September 24, 2022
SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer riskSofia I Vuorinen, Rachel K Okolicsanyi, Martina Gyimesi, et al.
Genes|June 27, 2024
Identification of Polymorphisms in EAAT1 Glutamate Transporter Gene SLC1A3 Associated with Reduced Migraine RiskCassie L Albury, Heidi G Sutherland, Alexis W Y Lam, et al.
Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine|February 3, 2018
suPAR is associated with risk of future acute surgery and post-operative mortality in acutely admitted medical patientsJeppe Meyer, Morten Alstrup, Line J H Rasmussen, et al.
Journal of Virology|August 21, 2020
Broad Anti-coronavirus Activity of Food and Drug Administration-Approved Drugs against SARS-CoV-2 In Vitro and SARS-CoV In VivoStuart Weston, Christopher M Coleman, Robert Haupt, et al.
Diabetologia|January 28, 2009
The risk allele load accelerates the age-dependent decline in beta cell functionA Haupt, H Staiger, S A Schäfer, et al.
The Journal of Infectious Diseases|February 10, 2009
Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccineSuzanne M Garland, Marc Steben, Heather L Sings, et al.
Growth Factors (Chur, Switzerland)|April 21, 2009
MRNA expression of members of the IGF system in the organ of Corti, the modiolus and the stria vascularis of newborn ratsJohann Gross, Astrid Machulik, Renate Moller, et al.
JAMA|November 18, 2024
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical TrialStephen J Nicholls, Wei Ni, Grace M Rhodes, et al.
Pediatric Hematology and Oncology|September 1, 1994
Increased risk of secondary leukemia after single-agent treatment with etoposide for Langerhans' cell histiocytosisR Haupt, T R Fears, P Rosso, et al.
Diabetes, Obesity & Metabolism|January 21, 2026
Eloralintide, a selective, long-acting amylin receptor agonist for treatment of obesity: Phase 1 proof of conceptShobha Bhattachar, Lai San Tham, Beth Tidemann-Miller, et al.
Pageof 255